AlphAIAlphAI — Financial news for AI agents
seekingalpha.com$MESO

Mesoblast GAAP EPS of -$0.04 beats by $0.08, revenue of $120.25M misses by $65.62M (NASDAQ:MESO)

Mesoblast reported FY GAAP EPS of -$0.04, beating estimates by $0.08, while revenue of $120.25M missed by $65.62M. Revenue grew 599.1% year-over-year. The company also received FDA approval for a new potency assay for Ryoncil.

Original reporting
seekingalpha.com
Published Oct 14, 2026, 12:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 12:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$MESO
Bearish
high confidence
Mentioned
$MESO
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$MESOBearishMed
01

Why it matters

The earnings release provides fresh guidance and performance metrics that were not previously public.

02

Market read

First-report earnings with a revenue miss; likely short-term price pressure.

03

What to watch

Potential upcoming FDA approval for Ryoncil assay could offset short-term revenue concerns.

Relevance 7/10Novelty 7/10Timing: pre-market today

Background

Mesoblast Limited (NASDAQ:MESO) is a clinical-stage biotech focused on regenerative medicine.

Company-level read

Ticker impact

$MESOBearishHigh confidence
Context

Mesoblast reported Q4 2026 GAAP EPS of -$0.04 beating expectations and revenue of $120.25M missing forecasts.

Expected impact

likely downside as market prices in the revenue shortfall

Evidence & confidence

Revenue fell short by $65.62M, a material miss for a $120M base, outweighing the modest EPS beat.

Market effects

Sector

Biotech sector may see broader scrutiny on revenue forecasts.

Regional

Australian biotech market could feel slight pressure.

Global

Limited to niche biotech investors.

Counterpoint

What could challenge this read

EPS beat could signal operational improvements; investors may focus on profitability over top-line.

Key entities

  • Company
    Mesoblast Limited

    Biotech firm reporting Q4 2026 results.

Read at source← All news

Related articles

$MESOMed

Operating cash spending at Mesoblast fell 86% from a year earlier to US$2.1 million.

Mesoblast reported an 86% drop in operating cash spending to $2.1M. Sales of Ryoncil® grew, and trials for rexlemestrocel-L in chronic pain and cardiovascular diseases advanced. FDA confirmed a BLA filing for rexlemestrocel-L in end-stage heart failure. The company met with FDA to discuss treatment for life-threatening gastrointestinal bleeding. Mesoblast is listed on Nasdaq (MESO) and ASX (MSB).

stocktitan.net
$MESOMedAI 8/10

Mesoblast completes Phase 3 trial dosing for chronic back pain therapy

Mesoblast (NASDAQ: MESO, ASX: MSB) completed patient treatment in its Phase 3 trial for rexlemestrocel-L, a therapy for chronic low back pain, with 350 patients enrolled. The company reported US$36M in Q4 revenue for Ryoncil, totaling US$115M for the year. Mesoblast also secured US$103M in cash after extinguishing debt. The company is pursuing FDA approvals for expanded uses of Ryoncil and rexlemestrocel-L.

scanx.trade
$MESOMedAI 8/10

The Big Business of Longevity: what is approved, what is only compounded, and who is actually getting paid

In 2024-2026, longevity advancements include FDA-approved MSC products, accelerated peptide approvals, and AI-designed drugs. GLP-1 medicines show cardiometabolic benefits. A gray market of wellness peptides exists, with FDA advisory votes on compounding. Mesoblast's Ryoncil gained FDA approval, and Longeveron's Laromestrocel targets aging-related conditions. Life Biosciences initiated a partial cellular reprogramming trial. Key players include Altos Labs, NewLimit, and Life Biosciences, with va

livetradingnews.com
$MESOHighAI 9/10

Mesoblast H2 Earnings Call Highlights

Mesoblast is conducting trials for RYONCIL in acute GVHD and Duchenne muscular dystrophy, with results expected in 2027. The company anticipates double-digit revenue growth and is pursuing approvals for rexlemestrocel-L in chronic low back pain and REVASCOR in heart failure. Mesoblast expects lower cash burn in fiscal 2027 and has a $125M credit facility.

yahoo.com